Document:

<PAGE>   1
                                                                    EXHIBIT 4.19

                          REGISTRATION RIGHTS AGREEMENT

         This Registration Rights Agreement (the "Agreement") is made this day
of April, 2000, between Genomic Solutions Inc., a Delaware corporation, 4355
Varsity Drive, Suite E, Ann Arbor, Michigan 48108 (the "Company") and Jeffrey S.
Williams, 7049 Suncrest Drive, Saline, Michigan 48176 (the "Holder").

         A. As of the date hereof, Holder is in possession of shares of the
Company's Common Stock.

         B. The Company and the Holder are entering into this Agreement to set
forth certain registration rights with respect to the Common Shares.

         NOW, THEREFORE, in consideration of the foregoing premises and other
good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:

1.       DEFINITIONS.  The following capitalized terms shall have the following
         definitions:

         (a) "Common Stock" means the Company's common stock, par value $.001,
         until the time that the Third Amended and Restated Certificate of
         Incorporation is effective, at which point the common stock becomes
         callable, until the expiration of the Call Period, as that term is
         defined in the Third Amended and Restated Certificate of Incorporation,
         and from the time of expiration of the Call Period, means the Company's
         common stock, par value $.001.

         (b) "IPO" means a registration statement filed with the Securities and
         Exchange Commission and declared effective relating to an initial
         public offering of common stock firmly underwritten by a nationally
         recognized underwriter who certifies to the Purchaser that such
         underwriter believes that (i) the offering will result in no less than
         $20,000,000 of gross proceeds to the Company and (ii) the securities
         offered will qualify for listing on the New York Stock Exchange or the
         National Market Tier of the Nasdaq Stock Market (an initial public
         offering that in fact results in no less than $20,000,000 of gross
         proceeds to the Company and the listing of the offered securities on
         the New York Stock Exchange or the National Market Tier of the Nasdaq
         Stock Market.

          (c) "Person" means an individual, a partnership, a limited liability
          company, a joint venture, a corporation, a trust, an unincorporated
          organization, a government or any department or agency thereof, or any
          other entity.

         (d) "Registrable Securities" means any shares of Common Stock issued or
         issuable with respect to the Common Shares by way of stock dividend,
         stock split or in connection with a combination of stock,
         recapitalization, merger, consolidation or other reorganization. As to
         any particular Registrable Securities, such securities will cease to be
         Registrable Securities on the earliest of the following dates: (i) the
         date such securities have been sold to the public pursuant to an
         offering registered under the Securities Act,

<PAGE>   2

         or (ii) the date such securities are eligible to be sold pursuant to
         Rule 144 (or any similar provisions then in force) under the Securities
         Act.

         (e) "Registration Period" means the period commencing immediately after
         the consummation of the IPO and ending on the fifth anniversary of the
         consummation of the IPO.

         (f) "Registration Statement" means any registration statement of the
         Company that covers any Registrable Securities pursuant to the
         provisions of this Agreement.

         (g) "SEC" means the Securities and Exchange Commission.

         (h) "Securities Act" means the Securities Act of 1933, as amended, or
         any similar federal law then in force.

2.       PIGGYBACK REGISTRATION.

         (a) If the Company proposes to register any of its securities under the
         Securities Act (other than pursuant to (i) an IPO; (ii) a registration
         on Form S-4 or any successor form, or (iii) an offering of securities
         in connection with an employee benefit plan, a stock option plan, a
         stock dividend plan, a stock ownership plan or a dividend reinvestment
         plan) at any time during the Registration Period and the registration
         form to be used may be used for the registration of Registrable
         Securities (a "Piggyback Registration"), the Company shall give prompt
         written notice to the Holder of its intention to effect such a
         registration (each a "Piggyback Notice") and, subject to Sections 2(b)
         and 2(c) below, the Company shall include in such registration all
         Registrable Securities with respect to which the Company has received
         written requests for inclusion therein within fifteen (15) days after
         the date of sending of the Company's notice (the "Included Registrable
         Securities"); provided, however, that, at the Company's option, the
         Company may file a separate Registration Statement for, and with
         respect to, Included Registrable Securities in satisfaction of the
         Company's obligation hereunder.

         (b) The registration rights granted to the Holder pursuant to Section 2
         (a) above are subordinate and subject to the rights of the holders of
         the Company's Series M Preferred Stock, Series B Preferred Stock,
         Series C Preferred Stock, Series D Preferred Stock and Series P
         Preferred Stock (collectively, the "Preferred Stock"), as more
         particularly described in the Shareholders Agreement, as amended,
         between the Company and certain of its stockholders, dated as of
         December 24, 1997, and amended and restated as of January 25, 2000, and
         the holders of registration rights under the April and October Business
         Loan Agreements dated April 23, 1999 and October 28, 1999 respectively
         (the "Warrantholders"). The Company shall be required to include the
         Holder's shares in any registration only to the extent that such
         inclusion will not reduce the amount of securities to be registered and
         sold by the holders of Preferred Stock and the Warrantholders. If the
         managing or principal underwriters named in the registration statement
         advise the Company that, in the good faith judgment of such managing or
         principal underwriters, the number of shares of Common Stock which the
         Holder, the Company and all other shareholders have requested to be
         included in such registration statement exceed the number of shares it
         is advisable to offer and to sell at such time,

<PAGE>   3

         then the Company shall include in such registration, to the extent of
         the number of shares of Common Stock which the Company is so advised
         can be sold in such offering, the shares of Common Stock that the
         Company proposes to issue and sell for its own account, the shares of
         Common Stock requested to be registered and sold by the holders of
         Preferred Stock and the Warrantholders and the number of shares of
         Common Stock to be registered and sold by the Holder and all other
         shareholders requesting registration.

         (c) If a Piggyback Registration is an underwritten secondary
         registration initiated by and on behalf of holders of the Company's
         securities other than the Holder of Registrable Securities pursuant to
         the exercise of demand registration rights, and the managing
         underwriters advise the Company in writing that in their opinion the
         number of securities requested to be included in such registration
         exceeds the number which can be sold in an orderly manner in such
         offering within a price range acceptable to the holders initially
         requesting such registration, the Company shall include in such
         registration (i) first, all of the securities requested to be included
         therein by the holder initially requesting such registration, and (ii)
         second, the Registrable Securities requested to be included in such
         registration and any other securities requested to be included in such
         registration, pro rata among the holders of Registrable Securities
         requesting such registration and the holders of such other securities
         on the basis of the number of shares owned by each such holder.

         (d) In the case of an underwritten Piggyback Registration, the Company
         shall have the sole and exclusive right to select the investment
         banker(s) and manager(s) to administer the offering.

3. REGISTRATION PROCEDURES. Whenever there has been a request to have any
Registrable Securities registered pursuant to this Agreement, the Company shall
use its reasonable best efforts to effect the registration and the sale of such
Registrable Securities in accordance with the intended method of disposition
thereof and pursuant thereto the Company shall as expeditiously as possible:

         (a) prepare and file with the SEC a Registration Statement with respect
         to such Registrable Securities and use its reasonable best efforts to
         cause such Registration Statement to become effective;

         (b) prepare and file with the SEC such amendments and supplements to
         such Registration Statement and the prospectus used in connection
         therewith as may be necessary to keep such Registration Statement
         effective for the period required by the intended method of
         disposition, and comply with the provisions of the Securities Act with
         respect to the disposition of all securities covered by such
         Registration Statement during such period in accordance with the
         intended methods of disposition by the sellers thereof set forth in
         such Registration Statement;

         (c) furnish the Holder such number of copies of such Registration
         Statement, each amendment and supplement thereto, the prospectus
         included in such Registration Statement (including each preliminary
         prospectus) and such other documents as the

<PAGE>   4

         Holder may reasonably request in order to facilitate the disposition of
         the Registrable Securities owned by the Holder;

         (d) use its reasonable best efforts to register or qualify such
         Registrable Securities under such other securities or blue sky laws of
         such jurisdictions as the Holder reasonably requests and do any and all
         other acts and things which may be reasonably necessary or advisable to
         enable the Holder to consummate the disposition in such jurisdictions
         of the Registrable Securities owned by the Holder (provided that the
         Company shall not be required to (i) qualify generally to do business
         in any jurisdiction where it would not otherwise be required to qualify
         but for this Section 3(d), (ii) subject itself to taxation in any such
         jurisdiction, (iii) consent to general service of process in any such
         jurisdiction, or (iv) qualify such Registrable Securities in a given
         jurisdiction where expressions of investment interest are not
         sufficient in such jurisdiction to reasonably justify the expense of
         qualification in the jurisdiction or where such qualification would
         require the Company to register as a broker or dealer in such
         jurisdiction).

         (e) notify the Holder of such Registrable Securities, at any time when
         a prospectus relating thereto is required to be delivered under the
         Securities Act, of the happening of any event as a result of which the
         prospectus included in such Registration Statement contains an untrue
         statement of a material fact or omits any material fact necessary to
         make the statements therein not misleading, and, at the request of the
         Holder, the Company shall prepare a supplement or amendment to such
         prospectus so that, as thereafter delivered to the purchasers of such
         Registrable Securities, such prospectus shall not contain an untrue
         statement of a material fact or omit to state any material fact
         necessary to make the statements therein not misleading;

         (f) use its reasonable best efforts to cause all such Registrable
         Securities to be listed on each securities exchange on which similar
         securities issued by the Company are then listed and to be qualified
         for trading on each system on which similar securities issued by the
         Company are from time to time qualified;

         (g) in the event of an underwritten public offering, enter into and
         perform its obligations under an underwriting agreement, in usual and
         customary form, with the managing underwriter(s) of such offering; and

         (h) in the event of the issuance of any stop order suspending the
         effectiveness of a Registration Statement, or of any order suspending
         or preventing the use of any related prospectus or suspending the
         qualification of any Common Stock included in such Registration
         Statement for sale in any jurisdiction, the Company shall use its
         reasonable best efforts to promptly obtain the withdrawal of such
         order.

The Holder agrees that, upon receipt of any notice from the Company of the
happening of any event of the kind described in Section 3(e) or (h) hereof, the
Holder shall forthwith discontinue disposition of shares of Common Stock
pursuant to a Piggyback Registration until receipt of the copies of an
appropriate supplement or amendment to the prospectus under Section 3(e) or
until the withdrawal of such order under Section 3(h).

<PAGE>   5

4. REGISTRATION EXPENSES. The Company shall bear all costs and expenses incident
to the Company' s performance of, or compliance with, this Agreement, including,
without limitation, all registration and filing fees, fees and expenses of
compliance with securities or blue sky laws, printing expenses, messenger and
delivery expenses, and fees and disbursements of counsel for the Company, all
independent certified public accountants of the Company and fees and expenses of
other Persons retained by the Company in connection with the distribution of the
Registrable Securities. The Holder shall pay all discounts and commissions
attributable to the Registrable Securities, all transfer taxes relating to the
sale or disposition of the Registrable Securities and all fees and expenses of
any attorney or accountant retained by the Holder in connection with the
registration of Registrable Securities.

5.       INDEMNIFICATION.

         (a) The Company agrees to indemnify, to the extent permitted by law,
         the Holder against all losses, claims, damages, liabilities and
         expenses caused by any untrue or alleged untrue statement of material
         fact contained in any Registration Statement, prospectus or preliminary
         prospectus or any amendment thereof or supplement thereto or any
         omission or alleged omission of a material fact required to be stated
         therein or necessary to make the statements therein not misleading,
         except insofar as the same are caused by or contained in any
         information furnished to the Company in writing by the Holder expressly
         for use therein or by the Holder's failure to deliver a copy of the
         Registration Statement or prospectus or any amendments or supplements
         thereto after the Company has furnished the Holder with a sufficient
         number of copies of the same. In connection with an underwritten
         offering, the Company shall indemnify such underwriters, their officers
         and directors and each Person who controls (within the meaning of the
         Securities Act) such underwriters to the same extent as provided above
         with respect to the indemnification of the Holder.

         (b) In connection with any Registration Statement in which the Holder
         is participating, the Holder shall furnish to the Company in writing
         such information as the Company reasonably requests for use in
         connection with any such Registration Statement or prospectus and, to
         the extent permitted by law, shall indemnify the Company, its directors
         and officers and each Person who controls (within the meaning of the
         Securities Act) the Company against any losses, claims, damages,
         liabilities and expenses resulting from any untrue or alleged untrue
         statement of material fact contained in the Registration Statement,
         prospectus or preliminary prospectus or any amendment thereof or
         supplement thereto or any omission or alleged omission of a material
         fact required to be stated therein or necessary to make the statements
         therein not misleading, but only to the extent that such untrue
         statement or omission is contained in any information so furnished in
         writing by the Holder; provided, however, that the obligation to
         indemnify under this Section 5(b) shall be several, not joint and
         several, among such holders of Registrable Securities.

         (c) Any Person entitled to indemnification hereunder shall (i) give
         prompt written notice to the indemnifying party of any claim with
         respect to which it seeks indemnification and (ii) unless in such
         indemnified party's reasonable judgment a conflict of interest between
         such indemnified and indemnifying parties may exist with respect to
         such claim, permit such indemnifying party to assume the defense of
         such

<PAGE>   6

         claim with counsel reasonably satisfactory to the indemnified party. If
         such defense is assumed, the indemnifying party shall not be subject to
         any liability for any settlement made by the indemnified party without
         its consent (but such consent shall not be unreasonably withheld). An
         indemnifying party who is not entitled to, or elects not to, assume the
         defense of a claim shall not be obligated to pay the fees and expenses
         of more than one counsel for all parties indemnified by such
         indemnifying party with respect to such claim, unless in the reasonable
         judgment of any indemnified party a conflict of interest may exist
         between such indemnified party and any other such indemnified parties
         with respect to such claim.

         (d) If for any reason the indemnification provided for in the preceding
         clauses (a) and (b) is unavailable to an indemnified party or
         insufficient to hold such party harmless as contemplated by the
         preceding clauses (a) and (b), then the indemnifying party shall
         contribute to the amount paid or payable by the indemnified party as a
         result of the loss, claim, damage, liability or expense in the
         proportion as is appropriate to reflect (i) the relative fault of the
         indemnified party and the indemnifying party, and (ii) any other
         relevant equitable considerations.

         (e) The indemnities provided in this Section 5 shall survive the
         Holder's transfer of any Registrable Securities.

6. PARTICIPATION IN UNDERWRITTEN REGISTRATIONS. No Person may participate in any
registration hereunder which is underwritten unless such Person (a) agrees to
sell such Person's securities on the basis provided in any underwriting
arrangements approved by the Person or Persons entitled hereunder to approve
such arrangements and (b) completes and executes all questionnaires, powers of
attorney, indemnities, underwriting agreements and other documents required
under the terms of such underwriting arrangements.

7. DISCLOSURE. With a view to making available to the Holder the benefits of
Rule 144 promulgated under the Securities Act, the Company agrees, for a period
of two years following the date of this Agreement, to:

         (a) make and keep public information available within the meaning of
         Rule 144(c) of the Securities Act at all times after ninety (90) days
         after the closing of the IPO;

         (b) file with the SEC in a timely manner all reports and other
         documents required of the Company under the Securities Act and the
         Securities Exchange Act of 1934, as amended (the "Exchange Act"); and

         (c) furnish to the Holder, so long as the Holder owns any Registrable
         Securities, forthwith upon request (i) a written statement by the
         Company that it has complied with the reporting requirements of Rule
         144 (at all times after ninety (90) days after the closing of the IPO)
         and the Exchange Act, (ii) a copy of the most recent annual or
         quarterly report of the Company, and (iii) such other reports,
         documents and other information in the possession of or reasonably
         obtainable by the Company as the Holder may reasonably request in
         availing themselves of Rule 144.

<PAGE>   7

8. MARKET STAND-OFF AGREEMENT. The Holder agrees that, for a period of 180 days
after the date of the final prospectus relating to an IPO, it shall not, either
directly or indirectly:

         (a) (x) offer, pledge, sell, contract to sell, sell any option or
         contract to purchase, purchase any option or contract to sell, grant
         any option, right or warrant to purchase, or otherwise transfer or
         dispose of, directly or indirectly, any shares of Common Stock or any
         securities convertible into or exercisable or exchangeable for Common
         Stock (including, without limitation, shares of Common Stock or
         securities convertible into or exercisable or exchangeable for Common
         Stock which may be deemed to be beneficially owned by the Holder in
         accordance with the rules and regulations of the Securities and
         Exchange Commission) or (y) enter into any swap or other arrangement
         that transfers all or a portion of the economic consequences associated
         with the ownership of any Common Stock (regardless of whether any of
         the transactions described in clause (x) or (y) is to be settled by the
         delivery of Common Stock, or such other securities, in cash or
         otherwise), without the prior written consent of the Company and the
         managing underwriter(s) of the IPO; and

         (b) make any demand for, or exercise any right with respect to, the
         registration of any shares of Common Stock or any securities
         convertible into or exercisable or exchangeable for Common Stock,
         without the prior written consent of the Company and the managing
         underwriter(s) of the IPO.

9.       MISCELLANEOUS.

         (a) The Company shall not hereafter enter into any agreement with
         respect to its securities which is inconsistent with or violates the
         rights granted to the Holder in this Agreement.

         (b) Any Person having rights under any provision of this Agreement
         shall be entitled to enforce such rights specifically to recover
         damages caused by reason of any breach of any provision of this
         Agreement and to exercise all other rights granted by law. The parties
         agree and acknowledge that money damages may not be an adequate remedy
         for any breach of the provisions of this Agreement and that any party
         may in its sole discretion apply to any court of law or equity of
         competent jurisdiction (without posting any bond or other security) for
         specific performance and for other injunctive relief in order to
         enforce or prevent violation of the provisions of this Agreement.

         (c) Except as otherwise provided herein, the provisions of this
         Agreement may be amended or waived only upon the prior written consent
         of the Company and the Holder.

         (d) All covenants and agreements in this Agreement by or on behalf of
         any of the parties shall bind and inure to the benefit of the
         respective successors and assigns of the parties hereto whether so
         expressed or not. In addition, whether or not any express assignment
         has been made, the provisions of this Agreement which are for the
         benefit of the Holder are also for the benefit of, and enforceable by,
         any subsequent holder of Registrable Securities.

<PAGE>   8

         (e) Whenever possible, each provision of this Agreement shall be
         interpreted in such manner as to be effective and valid under
         applicable law, but if any provision of this Agreement is held to be
         prohibited by or invalid under applicable law, such provision shall be
         ineffective only to the extent of such prohibition or invalidity,
         without invalidating the remainder of this Agreement.

         (f) This Agreement may be executed in any number of counterparts, each
         of which shall be deemed an original and all of which together shall
         constitute one and the same agreement. Photographic or facsimile
         reproductions of this Agreement may be made and relied upon to the same
         extent as the originals.

         (g) The descriptive headings of this Agreement are inserted for
         convenience only and do not constitute a part of this Agreement.

         (h) This Agreement shall be construed in accordance with the laws of
         the State of Delaware.

         (i) All notices, demands or other communications to be given or
         delivered under or by reason of the provisions of this Agreement shall
         be in writing and shall be deemed to have been given when delivered
         personally to the recipient, sent to the recipient by reputable express
         courier service (charges prepaid) or mailed to the recipient by
         certified or registered mail, return receipt requested and postage
         prepaid. Such notices, demands and other communications shall be sent
         to the Holder at the address indicated on the records of the Company
         and to the Company at the address indicated below:

                           4335 Varsity Drive, Suite E
                               Ann Arbor, MI 48108

         or to such other address or to the attention of such other person as
         the recipient party has specified by prior written notice to the
         sending party.

         IN WITNESS WHEREOF, the parties have signed this Agreement as of the
date set forth above.

COMPANY:
Genomic Solutions Inc., a Delaware Corporation

By:  /s/ Steven Richvalsky
   -------------------------------------------
Steven Richvalsky, Chief Financial Officer

HOLDER:

/s/ Jeffrey S. Williams
----------------------------------------------
Jeffrey S. Williams<PAGE>   1
                                                                    EXHIBIT 10.2

                   SALES, MARKETING AND DISTRIBUTION AGREEMENT

     THIS SALES, MARKETING AND DISTRIBUTION AGREEMENT (the "Agreement") is made
and entered into as of December 14, 1999 (the "Effective Date"), by and between
Genomic Solutions, Inc., a Delaware corporation, and PerkinElmer, Inc., a
Massachusetts corporation.

                                    RECITALS:

     Genomic Solutions, Inc. manufactures and distributes biochip systems,
protemic systems, gel analysis products and other products, software and systems
in the United States and throughout the world.

     Genomic Solutions, Inc. desires to hire PerkinElmer, Inc. to promote,
market and distribute its products and services and perform certain field
service responsibilities, subject to the terms and conditions of this Agreement.

     NOW THEREFORE, for and in consideration of the foregoing Recitals, the
mutual covenants and undertakings set forth below and other good and valuable
consideration, the receipt and adequacy of which are acknowledged, the
undersigned agree as follows:

1.   Definitions. The following terms shall have the meaning set forth in this
     section. All other capitalized terms shall have the meaning set forth in
     the section defining such terms.

     (a)  "Active Date" means January 1, 2000 or such other date as the parties
          shall mutually agree in writing.

     (b)  "Affiliates" of a party shall mean any person, corporation or other
          business entity controlled, controlled by or under common control with
          such party, with "control" meaning a fifty percent (50%) or greater
          ownership interest.

     (c)  "Core Markets" means the United States of America, the United Kingdom
          and Japan.

     (d)  "GSI" means Genomic Solutions, Inc. and its Affiliates.

     (e)  "GSI Products" means the products identified on Exhibit A hereto. In
          the event that during the Term, GSI offers any other products not
          described on Exhibit A, such products shall automatically be deemed
          "GSI Products" for purposes of this Agreement. GSI shall provide PKI
          with thirty (30) days advance written notice of the discontinuation of
          the manufacture of any GSI Product and the material modification or
          improvement of any GSI Product.

     (f)  "PKI" means PerkinElmer, Inc. and its Affiliates

     (g)  "Term" means the two (2) year period commencing on the Active Date,
          provided, that upon expiration of the initial Term, this Agreement
          shall automatically review for successive two (2)

<PAGE>   2

          year periods unless either party notifies the other in writing at
          least ninety (90) days prior to the expiration of the then current
          term of its intention not to renew.

2.   Preparation Activities.

     (a)  Preparation Sales. Commencing on the Effective Date, PKI may begin
          promoting the sale of the GSI Products and will work with GSI to
          prepare for the assumption of certain sales, marketing, distribution
          and field service activities on the Active Date. GSI shall be
          responsible for all sales and distribution activities world-wide prior
          to the Active Date (including all sales, marketing, distribution and
          service costs) and shall be entitled to receive all revenue from such
          activities. GSI shall also be entitled to all world-wide revenue from
          orders for GSI Products placed prior to the Active Date, so long as
          such GSI Products are actually shipped within one hundred eighty (180)
          days after the Active Date.

     (b)  Preparation Activities. Commencing on the Effective Date, GSI and PKI
          shall jointly and cooperatively prepare for PKI's distribution of GSI
          Products outside of Core Markets and promotion of GSI Products in the
          Core Markets as contemplated in Sections 3 and 4, respectively. GSI
          and PKI shall provide sufficient resources commencing on the Effective
          Date to allow PKI to undertake sales and distribution of GSI Products
          on the Active Date. Such preparation activities shall include, but not
          be limited to, the following:

          (i)   Training and preparation of PKI sales and field service forces,
                including account planning, quota setting, role definition and
                other sales preparation activities.

          (ii)  Incorporation of sales and service activities into PKI
                infrastructure, including logistics preparation and planning.

          (iii) Development of coordinated marketing launch and plan, including
                development of integrated message to customers, branding
                preparation and other launch related activities.

3.   Exclusive Distributor Appointment.

     (a)  Exclusive Rights and Responsibilities of PKI. Effective as of the
          Active Date and subject to the terms of this Agreement, PKI shall have
          the exclusive right and responsibility to engage in sales, marketing,
          distribution and field service activities with respect to GSI Products
          in any market or geographical area other than the Core Markets
          provided, however, that: (i) GSI has distributor contracts for
          non-Core Markets with those third parties listed in Exhibit B hereto,
          with territories and termination notice periods as set out in such
          Exhibit B for each such contract; and (ii) GSI shall send all of its
          distributors in the non-Core Markets as listed on Exhibit B notices of
          termination as soon as possible, but no later than four (4) days after
          the first date on which it may send such termination notices, through
          whatever means necessary to ensure that such third parties receive
          those notices as soon as possible (except the parties will work
          together in good faith to allow PKI to utilize Science & Technology,
          Ltd., the current distributor for GSI in New Zealand, from and after
          the Active Date).

<PAGE>   3

     (b)  Sales Goals and Quotas. GSI shall make GSI Products available to PKI
          in accordance with the terms and pricing in Section 7 below. Exhibit C
          attached is a schedule of PKI sales targets for the first four (4)
          quarters after the Active Date. Purchases of GSI Products in excess of
          the minimum sales target set forth in Exhibit C for any calendar
          quarter shall be credited towards the minimum sales target set forth
          therein for subsequent calendar quarters. These minimum sales targets
          are U.S. Dollar volumes based on GSI Product orders received by GSI
          from PKI on or before the last day of such calendar quarter, and are
          based on GSI's transfer price to PKI for such GSI Products. Exhibit C
          shall be reviewed and updated annually by the parties to set new
          quarterly minimum sales targets. In the event that parties are unable
          to agree on sales targets, the matter will be submitted for
          arbitration before a single arbitrator approved by the parties. All
          arbitration shall take place in accordance with the rules of the
          American Arbitration Association at such organization's Wilmington,
          Delaware offices. Such arbitrator shall make such adjustments based on
          then-current market conditions.

     (c)  Failure to Meet Minimum Sales. In the event that PKI fails to meet the
          quarterly minimum sales for GSI Products for three (3) consecutive
          calendar quarters, GSI, in its sole discretion and upon notice to PKI,
          may convert PKI's right to sell, market, distribute and provide field
          services for GSI Products outside of the Core Markets from exclusive
          to non-exclusive.

     (d)  Consideration. The consideration for the grant of exclusivity of
          distribution to PKI in the non-Core Markets shall consist of PKI's
          obligations under this Agreement to sell, market, distribute and
          service the GSI Products and other good and valuable consideration,
          the receipt and adequacy of which are acknowledged.

4.   Non-Exclusive Sales Representative Activities of PKI; PKI Providing
     Technical Assistance Services.

     (a)  Appointment of PKI as Sales Representative. PKI shall promote the
          products within the Core Markets, providing sales leads and opening
          access to PKI's broad network of customer relationships within the
          Core Markets. PKI shall therefore, from time to time after the Active
          Date, identify Leads in the Core Markets and communicate the identity
          of those Leads to GSI. GSI hereby appoints PKI, effective as of the
          Active Date, as a non-exclusive sales representative for the GSI
          Products in Core Markets. GSI further agrees that it will not, without
          first obtaining PKI's written consent (with such consent not to be
          unreasonably withheld) appoint any additional sales representatives,
          dealers, distributors or other agents in connection with the marketing
          and distribution of the GSI Products in the Core Markets after the
          Effective Date; except, however, that GSI may make customary changes
          in the ordinary course of business to its dealer/distributor network
          in Japan without first obtaining PKI's written consent.

     (b)  Sales Commissions. GSI shall pay sales commissions to PKI for sales
          procured as a result of assistance or efforts of PKI as follows:

           (i)   For all sales directly attributable to Leads or assistance
                 provided by PKI to GSI, GSI shall pay to PKI a commission based
                 on a percentage of the Net Revenue (as defined below) actually
                 received by GSI with respect to such sales. The commission
                 payable to PKI shall be between [*] and [*] of Net Revenue
                 actually received by GSI with respect to such sales, with the
                 commission amount to be determined based on the level of
                 assistance and effort provided by PKI Sales Personnel. By way
                 of example, PKI would receive a commission of [*] in instances
                 where GSI was unaware of any lead and a PKI sales
                 representative facilitates the sale, including without
                 limitation by making one or more sales calls. Likewise, PKI
                 shall receive a commission of [*] if GSI was aware of the lead
                 but PKI sales representatives assists in connection with the
                 sale. The commission for any particular sale shall be
                 determined based on the mutual agreement of the parties taking
                 into consideration the foregoing and the relative contributions
                 to the sale by the parties. For purposes of this section,
                 "Lead" means a qualified lead or prospect, including name of
                 company, key contact, defined need, reasonable indication of
                 finances, and other information to indicate that a relationship
                 has been established for a bona fide prospective purchaser of
                 GSI Products.

          (ii)  Timing of Payments. All commissions due and payable to PKI shall
                be paid by GSI to PKI within thirty (30) days after the end of
                the calendar quarter in which payment is actually received by
                GSI. Such commissions shall be paid in three separate checks,
                corresponding to the amounts earned in each of the three Core
                Markets.

          (iii) Definition of Net Revenue. For purposes of this Agreement, Net
                Revenue means the invoice amount of sales of GSI Products to end
                users attributable to Leads or assistance provided by PKI,
                excluding fees for personal or field services, software upgrade
                or maintenance services, freight charges, tariffs, taxes or
                similar charges and net of all discounts, returns and
                allowances, for (A) an initial purchase and subsequent purchases
                by an account during the six-month period immediately following
                such initial purchase; and thereafter (B) any subsequent
                purchases by such account, for which PKI sales personnel were
                directly involved in obtaining such purchases.

          (iv)  GSI shall deliver to PKI within forty-five (45) days after the
                end of each calendar quarter, beginning with March 31, 2000, a
                written report describing, for the applicable quarter: (A) GSI's
                Net Revenues subject to the commissions described in this
                Section 4(b); and (B) the Leads who have paid such amounts to
                GSI. Each such report shall be accompanied by full payment to
                PKI of the total commissions due to PKI for such Net Revenues.

          (v)   All commissions payable to PKI hereunder shall be paid in U.S.
                Dollars and there shall be no chargebacks against such
                commissions. To the extent that the Net Revenues upon which such
                commissions are computed are received by GSI in a currency other
                than U.S. Dollars, GSI shall convert such fees into U.S. Dollars
                in accordance with its normal accounting procedures.

          (vi)  In order for PKI to confirm full payment of the commissions due
                to PKI from GSI in accordance with this Section 4(b), GSI agrees
                to make and keep full and accurate books and records in
                sufficient detail to enable commissions payable hereunder to be
                determined. On thirty (30) days' prior written notice to GSI
                (but no more than twice during any calendar year), PKI's
                independent certified public accountants shall have full access
                to the books and records of GSI necessary to confirm the
                commissions which are due to PKI hereunder, and for no other
                purposes, and such accountants shall have the

          [*]   Certain information on this page has been omitted and filed
                separately with the Commission. Confidential treatment has been
                requested with respect to the omitted portion.

<PAGE>   4
                right to make copies therefrom at PKI's expense. PKI's
                independent certified public accountants shall have such access
                during normal business hours. Prompt adjustment shall be made by
                the proper party to compensate for any errors or omissions. PKI
                shall pay all costs of conducting audits pursuant to this
                Section 4(b)(vi); provided, however, that GSI shall reimburse
                PKI in full for PKI's reasonable out-of-pocket costs whenever an
                audit reveals that, with respect to any audited period, the
                underpayment of commissions due was greater than ten percent
                (10%) of the commissions actually paid to PKI for such period.
                PKI agrees to hold confidential all information learned in the
                course of any audit of GSI's books and records hereunder, except
                when it is necessary for PKI to reveal such information in order
                to enforce its rights under this Agreement, or except when
                compelled by law.

     (c)  All commissions due and owing to PKI hereunder but not paid by GSI on
          the due date thereof shall bear interest (in U.S. Dollars) at the rate
          of the lesser of: (i) twelve per cent (12%) per annum; and (ii) the
          maximum lawful interest rate permitted under applicable law. Such
          interest shall accrue on the balance of unpaid amounts from time to
          time outstanding from the date on which portions of such amounts
          become due and owing until payment thereof in full.

5.   PKI Obligations Generally.

     (a)  Product Labeling. All GSI Products shall be sold under the GSI name
          and logo which will be the predominant branding element. Both parties
          acknowledge and agree that the presence of PKI's "PerkinElmer" brand
          will facilitate market recognition, credibility and customer
          communications. Accordingly, PKI shall cooperate with GSI to design
          and produce a subordinated brand label for GSI Products distributed
          outside Core Markets (eg. "in partnership with PerkinElmer) and a
          miniature brand label (eg. "Perkin Elmer global alliance partner) for
          use in Core Markets. PE shall bear all of its own costs and expenses
          incurred in connection with such design activity and GSI shall bear
          its own cost in connection with production activities.

     (b)  Inventory and Production Forecasts. PKI shall provide GSI with a six
          month non-binding rolling production forecast of anticipated sales and
          GSI Products requirements. Such forecast shall be updated and
          delivered to GSI on a monthly basis for each of the particular
          countries where PKI will be undertaking sales activities. PKI shall
          also keep GSI reasonably informed of potential problems concerning the
          GSI Products. All shipments shall be made by GSI to PKI facilities or
          warehouses, with PKI (or its distributors) then responsible for
          further distribution to end-users.

     (c)  Marketing, Promotion and Sales Efforts. PKI shall use commercially
          reasonable efforts to market, promote the sale of, maintain and
          service the GSI Products in markets other than Core Markets and to
          market and promote the sale of GSI Products in Core Markets, subject
          to the other provisions of this Agreement. PKI shall provide and
          maintain, at its own expense, suitable facilities with adequate and
          efficient sales personnel and field engineers. PKI shall provide all
          ordinary service to its customers in markets outside the Core Markets
          as the nature of the business makes necessary or desirable in
          connection with the sale and distribution of GSI Products.

<PAGE>   5

     (d)  Promotional Materials. PKI will develop marketing and promotional
          material for generating leads and sales of the GSI Products at its
          sole cost and expense. Such materials shall conform with the labeling
          standards set forth in subsection (a) above and shall be subject to
          the approval of GSI.

     (e)  License to GSI Marks. GSI hereby grants to PKI a nonexclusive,
          royalty-free license during the Term to use GSI's name and any other
          trademarks or service marks associated with the GSI Products
          (collectively, the "GSI Marks") in connection with PKI's performance
          of its rights and obligations under this Agreement and to market and
          sell the GSI Products under such GSI Marks. Such license shall be
          non-transferable, except that PKI shall be entitled to grant its
          dealers and others to which it sells GSI Products a nonexclusive,
          nontransferable license to use such GSI Marks in connection with the
          marketing, promotion and sale of such GSI Products. PKI acknowledges
          that GSI is the sole and exclusive owner of all right, title and
          interest in and to the GSI Marks. At no time, whether during or after
          the term of this Agreement, shall PKI (i) represent, in any manner,
          that it has any right, title or interest whatsoever in or to the GSI
          Marks; (ii) use the GSI Marks in any way other than that expressly
          contemplated in this Agreement; (iii) register or attempt to register
          the GSI Marks or any mark or name similar to the GSI Marks under the
          laws of any jurisdiction; or (iv) cause or allow to be done any act or
          thing which would tend to impair the distinctiveness of the GSI Marks
          or any part of GSI's right, title and interest in the GSI Marks. In
          order to comply with GSI's quality control standards, PKI shall: (x)
          use the GSI Marks in compliance with all relevant laws and
          regulations; (y) accord GSI the right to inspect during normal
          business hours, without prior advance notice, PKI's facilities used in
          connection with efforts to sell the GSI Products in order to confirm
          that PKI's use of such GSI Marks is in compliance with this Section
          5(e); and (z) not modify any of the GSI Marks in any way and not use
          any of the GSI Marks on or in connection with any goods or services
          other than the GSI Products.

     (f)  License to PKI Marks. PKI hereby grants to GSI a nonexclusive,
          royalty-free license during the Term to use PKI's name and any other
          trademarks or service marks of PKI (collectively, the "PKI Marks") in
          connection with affixing co-branded labels to the GSI Products, in
          accordance with the co-branding arrangements contemplated herein. Such
          license shall be non-transferable, except that GSI shall be entitled
          to grant its sales representatives, dealers, distributors and other
          agents to which it sells GSI Products in the Core Markets a
          nonexclusive, nontransferable license to use such PKI Marks in
          connection with the marketing, promotion and sale of such GSI
          Products, subject to their compliance with GSI's obligations under
          this Section 5(f). GSI acknowledges that PKI is the sole and exclusive
          owner of all right, title and interest in and to the PKI Marks. At no
          time, whether during or after the term of this Agreement, shall GSI
          (i) represent, in any manner, that it has any right, title or interest
          whatsoever in or to the PKI Marks; (ii) use the PKI Marks in any way
          other than that expressly contemplated in this Agreement; (iii)
          register or attempt to register the PKI Marks or any mark or name
          similar to the PKI Marks under the laws of any jurisdiction; or (iv)
          cause or allow to be done any act or thing which would tend to impair
          the distinctiveness of the PKI Marks or any part of PKI's right, title
          and interest in the PKI Marks. In order to comply with PKI's quality
          control standards, GSI shall: (x) use the PKI Marks in compliance with
          all relevant laws and regulations; (y) accord PKI the right to inspect
          during normal business hours, without prior advance notice, GSI's
          facilities used in connection labeling the GSI Products in order to
          confirm that GSI's use of such PKI Marks is in

<PAGE>   6

          compliance with this Section 5(f); and (z) not modify any of the PKI
          Marks in any way and not use any of the PKI Marks on or in connection
          with any goods or services other than the GSI Products.

6.   Non-Competition.

     (a)  Reverse Engineering, etc. PKI shall not reverse engineer, redesign or
          disassemble or dismantle any GSI Products, except to the extent
          required to carry out the terms and conditions of this Agreement, in
          the biochip or proteomic area for the purpose of attempting to create
          products potentially competitive with the GSI Products. All such data
          regarding the GSI Products will be considered "confidential" for
          purposes of the Mutual Confidentiality Agreement between PKI and GSI
          of even date herewith. In the event that PKI engages in any activity
          as described in the first sentence of this subsection, then GSI may
          immediately terminate this Agreement.

     (b)  Sales of Competitive Products. In the event that PKI sells, markets or
          distributes, directly or indirectly, any products (other than GSI
          Products) which are competitive with any GSI biochip products (defined
          as any products which print or spot DNA on a glass slide or similar
          substrate) or competitive with any GSI proteomics products (defined as
          gels and mass spec products), then GSI shall have the right to convert
          the exclusive rights granted to PKI under Section 3 above to
          non-exclusive rights, upon giving PKI written notice of such
          conversion.

7.   Acceptance of Orders: Fulfillment; Pricing. The following terms shall
     apply for PKI ordering and sales outside of the Core Markets:

     (a)  Order Placement. PKI shall submit to GSI, its orders for the GSI
          Products in writing at least sixty (60) days before delivery is
          required for hardware, instruments and equipment and thirty (30) days
          before delivery is required for consumables, reagents and gels. All of
          PKI's orders for GSI Products consisting of consumables, reagents and
          gels (but excluding demonstration products) shall be for complete
          lots, the size of which shall be determined by GSI in its reasonable
          discretion. In this regard, GSI shall use reasonable efforts to
          minimize its lot sizes.

     (b)  Order Acceptance and Fulfillment. GSI shall give careful consideration
          to PKI's orders for GSI's Products, but all such orders shall be
          subject to GSI's approval and acceptance. If GSI does not communicate
          its rejection of an order to PKI within seven (7) days after receiving
          such order, then GSI shall be deemed to have accepted such order. GSI
          shall not be liable for any rejection of an order. All rejected orders
          shall be deemed purchased by PKI for the purposes of determining
          whether PKI has met the quarterly minimum sales targets in Exhibit C
          hereto. In the event of a shortage of GSI Products, GSI shall accept
          orders and allocate GSI Products in a reasonable manner so as to
          support PKI as a distributor of GSI Products, and at a minimum, GSI
          shall allocate its manufacturing capability on a unit basis so that
          PKI receives the same percentage of GSI's total output of GSI Products
          as PKI received on average during the most recent six (6) months prior
          to the shortage.

     (c)  Servicing and Certain Revenue. PKI shall be solely responsible for all
          installation, field servicing, maintenance and warranty repair with
          respect to GSI Products distributed by PKI

<PAGE>   7

          outside of Core Markets, provided, that GSI shall provide reasonable
          application and technical support to PKI marketing and sales
          personnel. PKI shall be entitled to receive all revenue generated from
          field servicing and maintenance outside of the Core Markets. Revenue
          from software upgrades and maintenance or subscription services shall
          be split equally by GSI and PKI.

     (d)  GSI Product Pricing. GSI shall sell the GSI Products to PKI at the
          transfer prices set forth on Exhibit A attached. If GSI develops any
          new products which constitute GSI Products at anytime after the Active
          Date, the parties shall negotiate in good faith toward reaching a
          mutual understanding as to the rate at which GSI shall sell such GSI
          Products to PKI. All orders of GSI Products by PKI shall be
          non-cancelable. The parties agree to annually evaluate the pricing of
          GSI with consideration to be given for adjustment based on market
          dynamics, the cost of products and services, and changing consumer
          conditions. In the event that the parties fail to reach agreement on
          product pricing, any price changes shall be subject to arbitration as
          provided in Section 3(b) above.

     (e)  F.O.B. All prices are and shall be, and all deliveries of GSI Products
          shall be made, F.O.B. GSI's U.S. or U.K. shipping dock. Risk of loss
          and title to the GSI Products passes to PKI at such F.O.B. point.

     (f)  Invoicing. All invoices for GSI Products shipped shall be due and
          payable in U.S. Dollars on or before the thirtieth (30th) day after
          the later of (i) the date the invoice is sent by GSI; and (ii) the
          date of shipment. All payments due and owing to GSI hereunder but not
          paid by PKI on the due date thereof shall bear interest (in U.S.
          Dollars) at the rate of the lesser of: (i) twelve per cent (12%) per
          annum; and (ii) the maximum lawful interest rate permitted under
          applicable law. Such interest shall accrue on the balance of unpaid
          amounts from time to time outstanding from the date on which portions
          of such amounts become due and owing until payment thereof in full

     (g)  Taxes. All prices for GSI Products shall be quoted or listed exclusive
          of any federal, state or local sales, use or excise taxes levied on or
          measured by the sale, sales price or use of GSI Products
          (collectively, "Taxes"). Unless PKI is exempted from such Taxes, all
          such prices shall be increased by the amount of the Taxes, if any, to
          which the GSI is subject in connection with the sale of the GSI
          Products.

     (h)  Resale Prices. PKI may sell the GSI Products at such prices and on
          such terms and conditions as it deems appropriate in its sole
          discretion. PKI shall have no authority to obligate GSI in any way
          through the terms and conditions on which it sells the GSI Products.

     (i)  Limited GSI Products Warranty. GSI will warrant all GSI Products
          (parts only) sold outside of Core Markets against defects in materials
          or workmanship for a period of twelve (12) months from the customer
          installation date under normal service and use; except that GKI will
          warrant consumables, gels and reagents for a period of ninety (90)
          days after shipment to the customer. The GSI Warranties shall not
          apply to any GSI Product which is used for a purpose or in a manner
          for which it was not intended, which is defectively or improperly
          installed, which is altered in any way other than in connection with
          its proper installation, or which is subject to misuse, negligence,
          accident or neglect, so as to affect adversely the condition,
          performance or

<PAGE>   8

          value of such GSI Product. GSI's obligations with respect to this
          warranty are limited to the repair and replacement of defective parts
          after GSI's inspection and verification of such defects. Such
          obligations specifically exclude labor costs.

     (j)  Disclaimer of Express and Implied Warranties. THE GSI WARRANTY ABOVE
          IS THE ONLY WARRANTY MADE WITH RESPECT TO THE GSI PRODUCTS OR ANY
          PARTS OR COMPONENTS THEREOF, EXPRESS OR IMPLIED. GSI MAKE NO IMPLIED
          WARRANTIES AND SPECIFICALLY DISCLAIMS ANY WARRANTY THAT ITS PRODUCTS
          ARE MERCHANTABLE OR FIT FOR ANY PARTICULAR PURPOSE.

     (k)  Remedy; Limitation of Liability. If PKI believes that GSI has breached
          any warranty it shall notify GSI of the way in which the GSI Product
          is defective and, upon request, shall return at GSI's expense the
          defective GSI Product or component part to GSI. If GSI agrees that the
          GSI Product is defective, it shall promptly repair or replace the
          defective GSI Product or issue a credit for the price of the GSI
          Product. EXCEPT WITH RESPECT TO THIRD PARTY PRODUCT LIABILITY CLAIMS
          ARISING FROM GSI PRODUCTS NOT CONFORMING TO THIS WARRANTY AND EXCEPT
          FOR GSI'S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8(b)(vi) BELOW, IN
          NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY
          PURCHASER OF GSI PRODUCTS FOR INDIRECT, SPECIAL, INCIDENTAL,
          EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, FOR LOSS OF ANTICIPATED
          PROFITS OR BUSINESS, OR FOR INTERRUPTIONS IN BUSINESS, WITH RESPECT TO
          ANY CLAIM OF ANY KIND RESULTING FROM THE GSI PRODUCTS OR THEIR USE OR
          MISUSE, ANY ORDER UNDER THIS AGREEMENT OR ANY PERFORMANCE,
          NON-PERFORMANCE OR BREACH OF THIS AGREEMENT, WHETHER THE BASIS OF SUCH
          LIABILITY IS BREACH OF CONTRACT, TORT (INCLUDING, WITHOUT LIMITATION,
          NEGLIGENCE AND STRICT LIABILITY), STATUTORY OR ANY OTHER LEGAL THEORY
          WHATSOEVER. The remedy set forth in this Section shall be PKI's sole
          and exclusive remedy for breach of GSI's warranties.

8.   Indemnity.

     (a)  PKI shall defend and hold harmless GSI, its Affiliates and all
          officers, directors, employees and agents thereof against and from any
          and all claims made against GSI based upon, arising out of or in any
          way related to (i) PKI's acts or omissions in connection with the
          sale, marketing, distribution, installation, maintenance and servicing
          of the GSI Products; (ii) PKI's conduct or operation of its business;
          (iii) any negligent acts or omissions of PKI or any of its agents,
          contractors or employees; (iv) any representations or warranties made
          by PKI with respect to the GSI Products which were not authorized by
          GSI; (v) any breach or violation of this Agreement; and (vi) PKI's
          failure to comply with relevant laws and regulations. Such indemnity
          shall extend to all costs, awards, claims or damages of any kind or
          nature, including attorney fees and related expenses ("Damages").

     (b)  GSI hereby agrees to indemnify, defend and hold harmless PKI, its
          Affiliates and all officers, directors, employees and agents thereof
          from all Damages arising out of (i) GSI's acts or omissions in
          connection with the production, sale, marketing, distribution,
          installation, maintenance and servicing of the GSI Products; (ii)
          GSI's conduct or

<PAGE>   9

          operation of its business; (iii) any negligent acts or omissions of
          GSI or any of its agents, contractors or employees; (iv) GSI's breach
          of this Agreement; (v) GSI's failure to comply with relevant laws and
          regulations; and (vi) PKI's use or reselling of the Products
          infringing on the intellectual property rights of third parties or
          constituting a misappropriation of any third party's trade secrets;
          provided, however, that with respect to part (vi) above:

          (A)  In the event that any GSI Product is held in a suit or proceeding
               to infringe any intellectual property rights of a third party and
               the use or reselling of such GSI Product is enjoined, or GSI
               reasonably believes that it is likely to be found to infringe or
               likely to be enjoined, then GSI shall, at its sole cost and
               expense, either (1) procure for PKI the right to continue
               reselling such GSI Product; or (2) modify such GSI Product so
               that it becomes non-infringing. If neither (1) nor (2) is
               practicable, then GSI may, in its sole discretion, cease
               distributing such GSI Product in the affected countries outside
               the Core Markets, in which case such GSI Product shall be deemed
               removed from this Agreement with respect to such affected
               countries upon repurchasing PKI's inventory of such GSI Product
               which are saleable and in the original packages and unaltered
               from their original form and design, subject to GSI's inspection,
               test, and acceptance. Any such repurchase of PKI's inventory of
               GSI Products shall be at the product prices indicated in Exhibit
               A hereto. Such repurchased inventory shall be shipped by PKI,
               freight and insurance to be paid by GSI, according to GSI's
               instructions. GSI shall pay PKI for such repurchased GSI Products
               within thirty (30) days after GSI receives those GSI Products in
               one of its facilities.

          (B)  GSI shall have no obligation for any claim of infringement
               arising from: (1) any combination of GSI Products with products
               not supplied or approved in writing by GSI, where such
               infringement would not have occurred but for such combination;
               (2) the adaptation or modification of GSI Products not approved
               by GSI, where such infringement would not have occurred but for
               such adaptation or modification; (3) the use of a GSI Product in
               an application for which it was not designed, intended or
               approved by GSI, where such infringement would not have occurred
               but for such use; (4) a claim based on intellectual property
               rights owned by PKI or any of its Affiliates; or (5) improper
               service or installation.

     (c)  The party seeking indemnification (be it GSI under Section 8(a) above
          or PKI under Section 8(b) above) (the "Indemnified Party") hereby
          agrees that: (i) the Indemnified Party shall give the other party (the
          "Indemnifying Party") prompt written notice of each such claim; (ii)
          the Indemnifying Party shall have sole control and authority with
          respect to the defense or settlement of any such claim; and (iii) the
          Indemnified Party shall cooperate fully with the Indemnifying Party,
          at the Indemnifying Party's sole cost and expense, in the defense of
          any such claim. Any settlement of any such claim that imposes any
          liability or limitation on the Indemnified Party shall not be entered
          into without the prior written consent of the Indemnified Party.

<PAGE>   10

     (d)  In the event a claim is based partially on an indemnified claim
          described in Sections 8(a) and/or 8(b) above and partially on a
          non-indemnified claim, or is based partially on a claim described in
          Section 8(a) above and partially on a claim described in Section 8(b)
          above, any payments and reasonable attorney fees incurred in
          connection with such claims are to be apportioned between the parties
          in accordance with the degree of cause attributable to each party.

     (e)  During the term of this Agreement, GSI shall maintain an occurrence
          based comprehensive general liability insurance policy issued by a
          reputable insurance company, naming PKI as an additional insured,
          which policy shall insure against any and all bodily injury and/or
          property damages for which GSI has agreed to indemnify PKI as stated
          above in this Section 8. Such insurance shall be in the amount of at
          least $1,000,000 per claim and $2,000,000 for claims in the aggregate.

9.   Assistance.

     (a)  Promotional Materials. GSI shall make available to PKI, such
          advertising, sales and promotional materials, price lists, sales
          assistance and other information concerning the GSI Products as GSI
          deems appropriate in its reasonable discretion. PKI shall not produce
          or cause to be produced any advertising, sales, promotional or other
          information concerning the GSI's Products without GSI's prior review
          and written consent, which shall not be unreasonably withheld or
          delayed. On termination of this Agreement by either party for any
          reason whatsoever, PKI shall immediately return to GSI any and all
          advertising, sales or promotional materials, price lists, copies of
          invoices and any and all other documents, materials or records
          pertaining to the GSI Products, whether produced by or at the
          direction of PKI or GSI.

     (b)  Technical Support and Assistance. GSI agrees to make reasonable
          efforts to answer any technical support inquiries which GSI receives
          from PKI.

10.  Early Termination.

     (a)  Termination by Either Party. Any provision of this Agreement to the
          contrary notwithstanding, either party shall have the right to
          terminate this Agreement, at any time without prior notice, except as
          required below, on the occurrence of any of the following:

          (i)   The other party fails, neglect or refuses in any material manner
                to satisfactorily perform the duties assigned to or required of
                it under this Agreement, but only after such other party has
                been given sixty (60) days notice of and opportunity to cure
                such failure, neglect or refusal;

          (ii)  The other party becomes insolvent or unable to pay its debts as
                they become due or makes an assignment for the benefit of its
                creditors;

          (iii) A receiver or a trustee is appointed for the other party's
                assets, and such receiver or trustee is not discharged within
                sixty (60) days of such appointment;
<PAGE>   11

          (iv)  A proceeding of any nature under the federal Bankruptcy Code, as
                amended, or any state insolvency statute, is commenced by or
                against the other party, and such proceeding, if involuntary, is
                not set aside within sixty (60) days from the date of its
                institution;

          (v)   Either party shall have the right to terminate this Agreement
                with ninety (90) days written notice given no later than sixty
                (60) days after the occurrence of the following two conditions:
                (A) the consummation of a bona fide initial public offering of
                GSI's capital stock that is firmly underwritten by a nationally
                recognized underwriter, that results in no less than $20,000,000
                of gross proceeds to GSI and that results in GSI's stock being
                listed for trading on the New York Stock Exchange or the
                National Market Tier of the Nasdaq Stock Market (defined herein
                as "IPO"), and (B) a post-IPO "change in control" of GSI,
                defined as the sale of all or substantially all of the business
                and assets of GSI or a sale of more than 50% of the issued and
                outstanding shares of GSI. The parties further agree that the
                foregoing right of termination shall not apply (X) merely
                because an IPO has occurred, or to an event that may be
                considered a change of control in GSI but does not follow an
                IPO, including by way of example, (Y) the sale of all or
                substantially all of the business and assets of GSI prior to an
                IPO or (Z) a sale of more than 50% of the issued and outstanding
                shares of GSI prior to an IPO.

     (b)  Termination by GSI. In addition to the foregoing, GSI may terminate
          this Agreement in the event that PE fails to make any required
          payments on the due date thereof and such failure is not cured within
          fifteen (15) days of notice by GSI to the addresses indicated in
          Section 14 below.

     (c)  Effect of Termination or Expiration. Upon termination or expiration of
          this Agreement, as the case may be, PKI shall have no right to market
          and distribute the GSI Products (except for the six-month period
          immediately following the effective date of termination or expiration,
          as the case may be, during which PKI shall be entitled to sell-off its
          inventory of GSI Products) and all licenses hereunder shall
          immediately terminate. PKI shall not be entitled to any commissions
          for sales closed after termination or expiration, regardless of
          whether PKI participated in the sale. In addition, each party shall
          return to the other party all copies of any promotional material,
          written literature, product samples, and any Confidential Information
          as herein defined. Termination and expiration shall not affect PKI's
          obligations with respect to GSI Products previously sold hereunder or
          with respect to any indebtedness owed by either party to the other.

     11.  RESERVED

12.  Dealer Status. Nothing in this Agreement shall be construed in such a
     manner as to constitute one party the agent or legal representative of the
     other party for any purpose whatsoever. Neither party shall have any
     authority whatsoever, whether express or implied, to assume, create or
     incur any obligation or liability whatsoever on behalf of or in the name of
     the other party, or to bind the other party in any manner whatsoever.
     Neither party shall be liable for any damages, loss, cost or expense
     whatsoever, including incidental or consequential damages, resulting from
     any sale or other activities performed by the other party.

<PAGE>   12

13.  Cooperative Exchange and Licensing. Attached as Exhibit D hereto is a list
     of representative PKI technologies. PKI agrees to license GSI, on a
     non-exclusive basis, the right to use those technologies to make, use and
     sell products for the proteomic market and/or for the biochip market. As
     GSI identifies each such use of those PKI technologies, the license fee
     level for such use will be set by the parties at then-current market rates,
     based upon the specific technology to be licensed and the intended use. GSI
     will receive a 30% discount on the agreed-upon license fees so long as: (i)
     this Agreement remains in effect; and (ii) PKI's rights under Section 3
     above remain exclusive. If either of these conditions (i) or (ii) is not
     met, then GSI will lose the 30% discount, but will maintain the license
     rights at the agreed-upon market rates. At the time the parties set the
     license fee level for each such use, they shall also negotiate in good
     faith to conclude the other terms and conditions of such license agreement.

14.  Notices. Any and all notices, requests, demands and other communications
     permitted under or required pursuant to this Agreement (each, a "notice")
     shall be in writing and shall be (i) personally delivered; (ii) sent by
     facsimile transmission (with a hard copy to follow in one of the other
     manners contemplated in this Section 14); (iii) sent via overnight courier,
     shipping charges prepaid; or (iv) sent via U.S. Mail, postage prepaid,
     certified mail, return receipt requested, to the parties at the addresses
     or fax numbers set forth below, or at such other addresses or fax numbers
     as they may indicate by written notice given as provided in this Section
     14.

         If to PKI:                           With a required copy to:

         PerkinElmer, Inc.
         45 William Street                    Hale and Dorr LLP
         Wellesley, Massachusetts  02481      60 State Street
                                              Boston, Massachusetts  02109
         Fax no: 781-431-4115                 Fax no.:  617-526-5000
         Attn: General Counsel                Attention:  David E. Redlick

         If to GSI:                           With a required copy to:

         Genomic Solutions Inc.               Jaffe, Raitt, Heur & Weiss,
         4355 Varsity Drive                   Professional Corporation
         Ann Arbor, MI  48108                 One Woodward Avenue, Suite 2400
         Fax:  (734) 975-4808                 Detroit, MI  48226
         Attn:  Jeff Williams                 Fax:  (313) 961-8358
                                              Attention:  Peter Sugar

     Any notice sent in the manner contemplated in clause (i) above shall be
     deemed to have been given on the date delivered; in the manner contemplated
     in clause (ii) above, as of the time the sender receives confirmation from
     its fax machine that the facsimile transmission has been successfully
     completed (provided, however, that if such time is after 4:00 p.m.,
     measured in terms of the recipient's local time, the notice shall be deemed
     to have been given as of 8:00 a.m. on the next business day of the
     recipient); in the manner contemplated in clause (iii) above, on the first
     (1st) business day after the notice has been deposited in a regularly-
     maintained receptacle for such a parcel; and in the manner contemplated in

<PAGE>   13
     clause (iv) above, on the third (3rd) business after the notice has been
     deposited in a regularly-maintained receptacle for U.S. Mail.

     Each party agrees that any press releases, publicity or advertising which
     shall be released by it in which the other party is identified shall
     require the prior written approval of such other party, such approval not
     to be unreasonably withheld or delayed.

15.  Non-Assignable. Neither party may assign this Agreement or its rights or
     obligations under this Agreement without the written consent of the other
     party; which consent may be granted or withheld in the other party's sole
     discretion.

16.  Waiver. Any party's waiver of any breach of any provision of this
     Agreement, and any party's failure to exercise any of its rights under or
     in connection with this Agreement, shall not operate or be construed as a
     waiver by such party of any subsequent or similar breach or of any such
     rights or preclude exercise of such rights at a later time.

17.  Choice of Law: Construction. This Agreement is deemed to have been executed
     in the State of Delaware and shall be construed and enforced in accordance
     with the laws of the State of Delaware, without regard to its conflict of
     laws principles. This Agreement shall not be construed against or in favor
     of any party by virtue of the fact that this Agreement was drafted
     primarily by any one party.

18.  Submission to Jurisdiction. The parties irrevocably submit to the
     jurisdiction of the federal and state courts of Wilmington, Delaware;
     provided, however, that nothing herein shall preclude -------- -------
     either party, if it thinks fit, from instituting proceedings against the
     other party or anyone acting by, through or under the other party in any
     place which may have jurisdiction for the purpose of protecting and
     enforcing such Party's rights either hereunder or pursuant to any other
     agreements, documents, instruments or otherwise. Each party hereby
     irrevocably waives any objection which it may now or hereafter have to the
     laying of venue of any suit, action or proceeding relating to this
     Agreement in Wilmington, Delaware, and further irrevocably waives any claim
     that Wilmington, Delaware is not a convenient forum for any such suit,
     action or proceeding.

19.  Remedies. Any remedy provided in this Agreement for a breach of a specific
     section of this Agreement shall be the sole and exclusive remedy for the
     breach to which it relates. Subject to the preceding sentence, the parties'
     respective rights and remedies under or with respect to breaches of this
     Agreement which are not specifically provided for in this Agreement are
     separate and cumulative, and no one of them, whether or not exercised,
     shall be deemed to be an exclusion of any of the others and shall not limit
     or prejudice any other legal or equitable right which any party to this
     Agreement may have.

20.  Entire Agreement; Amendment. This Agreement represents the complete and
     final expression of the parties' agreements and understandings with respect
     to its subject matter. This Agreement supersedes all other prior oral and
     written agreements between the parties with respect to the subject matter
     of this Agreement. Except to the extent expressly provided in this
     Agreement, this Agreement may not be amended or modified except pursuant to
     a written agreement executed by both parties.

<PAGE>   14

21.  Binding Effect. This Agreement shall be binding on an inure to the benefit
     of the parties and their respective successors and permitted assigns.

22.  Headings. The headings contained in this Agreement are for reference
     purposes only and shall not in any way affect the meaning or interpretation
     of this Agreement.

23.  No Third-Party Beneficiaries. This Agreement, and the respective
     obligations of PKI and GSI under this Agreement, are for the sole and
     exclusive benefit the parties to this Agreement. Any provision of this
     Agreement to the contrary notwithstanding, no party other than PKI, GSI and
     their respective successors and permitted assigns shall have the right to
     rely on or enforce the provisions of this Agreement as a third-party
     beneficiary or otherwise.

24.  Offset. Each party shall be entitled to offset any amounts due it by the
     other party against any amounts which it owes the other party.

25.  Pronouns. References to a party in the singular or plural, as him, her, it
     or other like preferences, shall also, where the context so requires, be
     deemed to include the singular or the plural, or masculine, feminine or
     neuter reference, as the case may be.

26.  Counterparts; Facsimile Signatures. This Agreement may be executed in
     counterparts, each of which shall be deemed an original and all of which
     together shall constitute one instrument. Facsimile or photostatic copies
     of signatures to this Agreement shall be deemed to be originals and may be
     relied on to the same extent as the originals.

27.  Severability. If any provision of this Agreement is declared invalid or
     unenforceable by a court having competent jurisdiction, it is mutually
     agreed that this Agreement shall endure except for the part declared
     invalid or unenforceable by order of such court. The parties shall consult
     and use their best efforts to agree upon a valid and enforceable provision
     which shall be a reasonable substitute for such invalid or unenforceable
     provision in light of the intent of this Agreement

     IN WITNESS WHEREOF, the undersigned have executed and delivered this Sales,
Marketing and Distribution Agreement as of December 14, 1999.

                             Genomic Solutions, Inc.

                             By: Jeffrey S. Williams
                                -----------------------------------
                             Its: President & CEO
                                 ----------------------------------
                             PerkinElmer, Inc.

                             By: Terrance Carlson
                                -----------------------------------
                             Its: SR V.P.
                                 ----------------------------------

<PAGE>   15

                                    EXHIBIT A

                                  GSI PRODUCTS

                          LIST PRICE AND TRANSFER PRICE

<TABLE>
<CAPTION>
------- ----------------------- ----------------------------------------------------------------
        CATEGORY                PRODUCT                                         GSI       PKI
                                                                                LIST   TRANSFER
                                                                               PRICE     PRICE
<S>     <C>                     <C>                                           <C>      <C>
------- ----------------------- ----------------------------------------------------------------

1       BioChip Systems         GeneTAC 2000                                  $ 80,000    [*]
------- ----------------------- ------------------------------------------------------
2       BioChip Systems         GeneTAC 3000                                  $ 99,000    [*]
------- ----------------------- ------------------------------------------------------
3       BioChip Systems         Flexys Gridding System                        $ 80,000    [*]
------- ----------------------- ------------------------------------------------------
4       BioChip Systems         Flexys Gridding with Autoloader               $150,000    [*]
------- ----------------------- ------------------------------------------------------
5       BioChip Systems         Flexys Picking System                         $ 90,000    [*]
------- ----------------------- ------------------------------------------------------
6       BioChip Systems         Flexys Picking with Autoloader                $160,000    [*]
------- ----------------------- ------------------------------------------------------
7       BioChip Systems         Flexys High Density Arraying                  $ 80,000    [*]
------- ----------------------- ------------------------------------------------------
8       BioChip Systems         Flexys High Density Arraying with Autoloader  $150,000    [*]
------- ----------------------- ------------------------------------------------------
9       BioChip Systems         Hybridization Station 12 Slide                $ 59,000    [*]
------- ----------------------- ------------------------------------------------------
10      Proteomic Systems       2-D Electrophoresis System                    $ 13,700    [*]
------- ----------------------- ------------------------------------------------------
11      Proteomic Systems       Gel Processor                                 $ 29,000    [*]
------- ----------------------- ------------------------------------------------------
12      Proteomic Systems       Proteomic Analyzer System (Darkroom)          $ 55,000    [*]
------- ----------------------- ------------------------------------------------------
13      Proteomic Systems       Proteomic Software only                       $ 25,000    [*]
------- ----------------------- ------------------------------------------------------
14      Proteomic Systems       Proteomic Analyzer System (Scanner)           $ 30,000    [*]
------- ----------------------- ------------------------------------------------------
15      Proteomic Systems       ProGest                                       $ 65,000    [*]
------- ----------------------- ------------------------------------------------------
16      Proteomic Systems       ProMS                                         $ 55,000    [*]
------- ----------------------- ------------------------------------------------------
17      Proteomic Systems       Flexys Proteomics system (Protein Picker)     $127,000    [*]
------- ----------------------- ------------------------------------------------------
18      Proteomic Systems       Maldi Mass Spec                               $265,000    [*]
------- ----------------------- ------------------------------------------------------
19      Gel Analysis            GelPrint 2000i                                $ 13,500    [*]
------- ----------------------- ------------------------------------------------------
</TABLE>

NOTE:    Destination shipping charges are not included.
         Shipping terms:  FOB GSI's U.S. or U.K. shipping dock.

         Consumables, gels and reagents offered by GSI will be made available to
         PKI at [*] of GSI's List Price for such materials, as in effect on the
         date PKI's purchase order is received by GSI.

[*]      Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with respect to
the omitted portion.

                                      -16-

<PAGE>   16

                                    EXHIBIT B

                     GENOMIC SOLUTIONS' DISTRIBUTOR SCHEDULE

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
      DATE OF AGREEMENT            AGREEMENT WITH                    TERMINATION ASSUMING DEFINITIVE       COUNTRY
                                                                     AGREEMENT SIGNED DEC. 15, 1999
<S>                           <C>                                    <C>                              <C>
-----------------------------------------------------------------------------------------------------------------------------
          12/15/98            Science & Technology Ltd.              December 15, 2000*               New Zealand
-----------------------------------------------------------------------------------------------------------------------------
           2/15/99            Bio/Can Scientific                     January 14, 2000                 Canada
-----------------------------------------------------------------------------------------------------------------------------
           12/7/98            B&L                                    March 15, 2000                   Benelux
-----------------------------------------------------------------------------------------------------------------------------
           5/26/99            Proteigene SARL                        March 15, 2000                   France
-----------------------------------------------------------------------------------------------------------------------------
           3/16/99            Biogenet                               March 16, 2000                   Poland
-----------------------------------------------------------------------------------------------------------------------------
           3/31/99            Seoulin Scientific Co., Ltd.           March 31, 2000                   South Korea
-----------------------------------------------------------------------------------------------------------------------------
           3/26/99            AbiMed                                 June 15, 2000                    Germany
-----------------------------------------------------------------------------------------------------------------------------
           8/30/99            Sinc Do Brasil Inst.Cientifica         August 30, 2000                  Brazil
-----------------------------------------------------------------------------------------------------------------------------
           9/18/99            Labmate (Asia) PVT. LTD                September 22, 2000               India
-----------------------------------------------------------------------------------------------------------------------------
          11/16/98            Australian Laboratory Services         November 16, 2000                Australia
-----------------------------------------------------------------------------------------------------------------------------
           12/3/98            Feng Jih                               December 3, 2000                 Taiwan and China
-----------------------------------------------------------------------------------------------------------------------------
              ?               Bio Tech A.S.                          March 15, 2000**                 Czech Republic
-----------------------------------------------------------------------------------------------------------------------------
           12/3/98            Feng Jih                               December 3, 2000                 Taiwan and China
-----------------------------------------------------------------------------------------------------------------------------
</TABLE>

*CURRENT PKI DISTRIBUTOR
**NO CONTRACT CAN BE LOCATED.  GSI BELIEVES IT CAN CANCEL THIS AGREEMENT WITH
  90 DAYS NOTICE.

<PAGE>   17

                                    EXHIBIT C

                                PKI SALES TARGETS

<TABLE>
<CAPTION>

Calendar Quarter                     MINIMUM
----------------                     -------
<S>                                 <C>
Q1, 2000                               [*]
Q2, 2000                               [*]
Q3, 2000                               [*]
Q4, 2000                               [*]
</TABLE>

Note:  These minimums are dollar volume of sales based on orders received by GSI
from PKI and are at GSI's transfer price to PKI.

[*]    Certain information on this page has been omitted and filed separately
       with the Commission. Confidential treatment has been requested with
       respect to the omitted portion.

<PAGE>   18

                                    EXHIBIT D

                                PKI TECHNOLOGIES

                                      [*]

[*]     The information on this page has been omitted and filed separately with
        the Commission. Confidential treatment has been requested with
        respect to the omitted portion.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}]]